Clinical trials: Controlled Hypertension
Difficult to Control Hypertension
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory…
- Trial name
- BOLD-HTN (NCT06343298)
- Testing
- MANP
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- E-Star BioTech, LLC
Glaucoma
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide 1% ophthalmic suspension (manufactured…
- Trial name
- NCT02512042
- Testing
- Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension
- Where
- 10 sites in United States
- Volunteers
- 973 people
- Sponsor
- Actavis Inc.
Essential Hypertension
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
CS-8635 combines three widely prescribed antihypertensive medications, olmesartan medoxomil(OM), amlodipine (AML), and hydrochlorothiazide (HCTZ), to lower blood pressure.
- Trial name
- NCT01838850
- Where
- 39 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Renal Pelvis Cancer, Restless Legs Syndrome
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in the Adverse Events…
- Conditions
- Renal Pelvis Cancer, Restless Legs Syndrome, Epilepsy, Neuropathic Pain
- Trial name
- NCT01138124
- Testing
- Gabapentin prescriptions
- Volunteers
- 54,202 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Hypertension
CKD-330 Phase 3 Trial in Amlodipine Non-responder
Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy
- Trial name
- NCT02586311
- Testing
- CKD-330 16/5mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Ocular Hypertension
FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension
A PHASE 1/2A, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF FM101 IN PATIENTS WITH OCULAR HYPERTENSION, AND TO ASSESS THE RELATIVE BIOAVAILABILITY OF THE…
- Trial name
- NCT04585100
- Testing
- FM101 tablet, FM101 oral solution, FM101 150 mg
- Where
- 5 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Future Medicine
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension
The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension
The purpose of this clinical study is to evaluate and compare the efficacy and safety of Fimasartan (60mg / 120mg) with Candesartan(8mg) in patients with mild to moderate hypertension.
- Trial name
- NCT01135212
- Testing
- Fimasartan 60mg, Fimasartan 120mg, Candesartan cilexetil
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Hypertension
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not…
- Trial name
- NCT00700271
- Testing
- Amlodipine, Valsartan
- Where
- 2 sites in France, Tunisia
- Volunteers
- 478 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.
- Trial name
- NCT00368277
- Testing
- Aliskiren, Ramipril, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 901 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open Angle Glaucoma (POAG)
One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the intraocular pressure (IOP) lowering effect of one, two, or three iStent devices in eyes of subjects previously on two anti-glaucoma medications.
- Trial name
- NCT01517477
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Pulmonary Arterial Hypertension
Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
Study of PAH Subjects with LTOT Use that have Demonstrated Improved Exercise Tolerance with the use of Inhaled Nitric Oxide
- Trial name
- NCT03602781
- Testing
- iNO
- Where
- 4 sites in United States, Canada
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Selonsertib in Adults With Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH).
- Trial name
- ARROW (NCT02234141)
- Testing
- Selonsertib
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 151 people
- Sponsor
- Gilead Sciences
Uncontrolled Hypertension
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
The purpose of this clinical trial is to measure the safety and efficacy of RTN-001 in adult participants with uncontrolled hypertension versus placebo.
- Trial name
- NCT07142356
- Testing
- RTN-001
- Where
- 44 sites in United States
- Volunteers
- 280 people
- Sponsor
- Retension Pharmaceuticals. Inc.
Pulmonary Arterial Hypertension
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.
- Trial name
- IMPROVE-PAH (NCT07365332)
- Testing
- IKT-001
- Where
- 43 sites in United States, Argentina and 12 more
- Volunteers
- 486 people
- Sponsor
- Inhibikase Therapeutics
Hypertension
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
- Trial name
- NCT00389519
- Testing
- ramipril
- Where
- 100 sites in United States, Argentina and 7 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Portal Hypertension
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.
- Trial name
- NCT00737594
- Testing
- Cobiprostone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sucampo Pharma Americas, LLC